MedTrace Logo

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

NCT01975701 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2019-12-04

Study results available
· View outcomes & findings →

Summary

This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3.

Conditions

  • Recurrent Glioblastoma or Other Glioma Subtypes

Interventions

DRUG

BGJ398

Capsule for oral use.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-09
Primary Completion
2018-10-03
Completion
2018-10-03
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Netherlands
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01975701 on ClinicalTrials.gov